SEC Filing Summary: BioDrain Medical, Inc. (10-Q)
Business Context and Reporting Period
Company: BioDrain Medical, Inc. (Note: Input metadata referenced "Axe Compute Inc.", but the filing text identifies the registrant as BioDrain Medical, Inc.)
Period: Quarterly report for the period ended June 30, 2012.
Business Stage: Development stage company focused on the STREAMWAY® Fluid Management System (FMS) for collecting and disposing of infectious fluids in surgical settings. The company received FDA 510(k) clearance in April 2009 but has limited sales history.
Going Concern: The filing explicitly states that recurring losses and a stockholders' deficit raise substantial doubt about the company's ability to continue as a going concern.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2012 | Six Months Ended June 30, 2011 |
|---|---|---|
| Revenue | $47,595 | $2,374 |
| Net Loss | $(2,849,142) | $(864,819) |
| Loss Per Share (Basic & Diluted) | $(0.06) | $(0.04) |
| Cash Balance (End of Period) | $35,283 | $57,638 |
| Net Cash Used in Operating Activities | $(644,105) | $(807,783) |
| Total Current Liabilities | $2,447,489 | $2,353,268 |
| Convertible Debt (Current Portion) | $1,206,082 | $1,055,559 |
| Stockholders' Deficit | $(2,268,120) | $(2,703,264) |
Liquidity: Cash on hand is critically low at $35,283. The company relies heavily on debt financing and equity issuances to fund operations.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased significantly to $47,595 from $2,374 in the prior year period, driven by sales of disposable supplies to existing customers.
- Expense Surge: General and Administrative (G&A) expenses jumped by approximately $1.93 million. This was primarily due to a $1.74 million non-cash expense for investor stock compensation.
- Debt Restructuring: Significant activity in converting debt to equity occurred during the period. The company issued millions of shares to satisfy convertible notes and accounts payable.
- Stock Issuance: Outstanding common shares increased from 32,074,000 (Dec 31, 2011) to 67,316,108 (June 30, 2012), reflecting massive dilution to settle obligations and raise capital.
Guidance, Outlook, Risks, and Unusual Items
- Capital Needs: Management estimates a need to raise at least $2 million to fund operations for the next 12 months. Current cash is insufficient.
- Debt Defaults: As of August 13, 2012, the company had approximately $971,000 in principal and accrued interest on debts that are past due or in default. Creditors representing $418,000 have threatened legal action.
- Related Party Settlement: A critical settlement and forbearance agreement was reached on August 13, 2012, with Dr. Samuel Herschkowitz and SOK Partners. This involved issuing 26.5 million shares and adjusting conversion prices to $0.014 per share to avoid immediate enforcement of security interests.
- Management Changes: Joshua Kornberg was appointed CEO/President in July 2012. New employment agreements were signed for the CEO, COO, and CFO in August 2012, including significant equity grants.
- Legal Proceedings: The company is defending against a lawsuit filed by a former VP of Sales and Marketing alleging breach of contract and defamation.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to raise the required $2 million given the current cash balance of $35,283 and ongoing defaults.
- Dilution Impact: Assess the impact of the recent issuance of 26.5 million shares to Dr. Herschkowitz and SOK Partners, which now control approximately 65% of the outstanding common stock.
- Debt Conversion Terms: Review the adjusted conversion price of $0.014 per share for the Herschkowitz and SOK notes, which could result in the issuance of approximately 42.7 million additional shares.
- Going Concern Status: Confirm if the settlement with major creditors sufficiently mitigates the risk of involuntary bankruptcy proceedings.
- Revenue Sustainability: Determine if the revenue increase is sustainable or merely a one-time sale of consumables to existing evaluation units.